Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biocon Limited ( (IN:BIOCON) ) has shared an announcement.
Biocon Limited announced that the U.S. FDA has classified its Biocon Biologics’ Drug Substance Facility in Bengaluru as Voluntary Action Indicated (VAI) following an inspection. This classification pertains to the production of Human Recombinant Insulin and Biosimilar Pegfilgrastim Drug Substance for the U.S. market, reinforcing Biocon’s commitment to maintaining high standards of quality and compliance.
More about Biocon Limited
Biocon Limited is a prominent player in the biotechnology industry, primarily focusing on the development and production of biopharmaceuticals. The company specializes in manufacturing biosimilars, generic biologics, and novel biologics, with a significant market focus on providing affordable healthcare solutions globally.
Average Trading Volume: 122,237
Technical Sentiment Signal: Strong Buy
Current Market Cap: 524.6B INR
Learn more about BIOCON stock on TipRanks’ Stock Analysis page.